IE
AGIO icon

Israel Englander’s Agios Pharmaceuticals AGIO Stock Holding History

Israel Englander’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$544K – 5647
2025
Q4 		$544K Buy
+20,000
New +$702K ﹤0.01% 4888
2017
Q1 		– Sell
-50,000
Closed -$2.09M – 3448
2016
Q4 		$2.09M Buy
+50,000
New +$2.62M ﹤0.01% 1853

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Israel Englander's AGIO Position: Q2 2026 in Review

Israel Englander sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 32,144 shares — an estimated $1.09M sold.

Israel Englander first reported a position in AGIO in Q1 2014 and held it in 37 quarters. The position peaked at $35.2M in Q1 2016. 237 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Israel Englander reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 32,144 Agios Pharmaceuticals shares in Q2 2026, an estimated $1.09M.
  • Israel Englander first reported a position in Agios Pharmaceuticals in Q1 2014 and held it in 37 quarters.
  • Israel Englander's Agios Pharmaceuticals position peaked at $35.2M in Q1 2016.
  • 237 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.